HOVON HO59

Archived

Main info

Identifier:
HOVON 59 AML SAKK OSHO
Sponsor:
HOVON
Included patients:
22
Active sites:
5
(of 5)
Title:

Anti-CD33 antibody (Gemtuzumab Ozogamicin) prior to allografting with reduced intensity conditioning in patients with acute myelocytic leukemia (AML) or myelodysplasia: a phase II feasibility study.

Timeline

Scheduled
Actual
2004
15 Apr
First Site
2004
16 Apr
Activated
2004
12 May
FPI
2005
27 May
ClosedForInclusionActualStart
2005
27 May
CloseoutInProgressLastPtOutActualStart
2015
27 May
Archived

Details

Phase:
Prospective Phase II study
Monitoring Type:
Objectives:

Eligibility

Inclusion Criteria:
  • HLA identical sibling donor, or molecularly matched (9/10 or 10/10) unrelated donor
  • Donor must consent to hematopoietic stem cell harvest from peripheral blood (preferably) or from bone marrow
  • Donor meets the institutional guidelines for stem cell harvest
  • Age = 16 years or = 75 years
Exclusion Criteria:
  • Pregnancy
  • HIV positivity
  • Current serious systemic illness

Participating Sites

Site
5 results
Order by
Accrual rate
Activation date
NL-Rotterdam-EMCDANIEL
14
NL-Utrecht-UMCUTRECHT
3
NL-Amsterdam-AMC
2
NL-Amsterdam-VUMC
2
NL-Rotterdam-ERASMUSMC
1
= Active hospitals
= Inactive hospitals

Participating Parties

Downloads

Up